

4BioDx® antibodies: bringing the right tools to study Tau and neurodegeneration

Nicolas Sergeant^{1,2}, Sara Carracedo², Yolanda Ramos Escuredo², Claude-Alain Maurage¹, Raphaelle Caillierez¹, Sabihia Eddarkaoui¹, Maryse Delehedde² and Luc Buée^{1,2}

Univ. Lille, Inserm, CHU-Lille, UMR S1172, F-59045 Lille, France 1. SPQI - 4BioDx Company, F-59045 Lille 2.



Introduction: Who is SPQI - 4BioDx?

SPQI (Services et Produits de Qualité et Innovants) develops, produces and commercializes laboratory reagents for research (monoclonal antibodies, polyclonal antibodies) under the 4BioDx® brand (www.4BioDx.com). The company SPQI is a spin-off of prestigious research institutes namely INSERM UMRS1172 ("Institut National de la Santé et de la Recherche Médicale") headed by Pr Luc Buée, the CNRS ("Centre National de la Recherche scientifique"), the University of Lille and the Lille Hospital in North of France (CHRU de Lille). All our antibodies are validated by our scientific teams with more than 25 year experiences in neurodegenerative diseases and by many peer-reviewed publications.



Examples of 4BioDx products and main applications

Anti-Tau [pS422] Mouse Monoclonal Antibody - Ref. 4BDX-1501

The monoclonal antibody Clone 2H9 (Ref. 4BDX-1501) is directed against phospho-Ser422 Tau, a pathological Tau phospho-epitope in neurological disorders. This antibody is useful by immunoblotting to detect pS422 epitope in brain homogenates from patients presenting a Tauopathy. By immunohistochemistry, this reference has been shown to label neurofibrillary tangles in Alzheimer patients and in Tau transgenic mouse brain sections.

This monoclonal antibody is also suitable for immunotherapy in experimental models of Tauopathies (Troquier et al. 2012).


This specific biomarker of neurofibrillary degeneration is actually the only one mouse monoclonal antibody on the market.



Immunofluorescence of Thy-Tau22 transgenia mouse model of neurofibrillary degeneration



unohistochemistry of Thy-Tau22 transgenio model of neurofibrillary degeneration



Applications WB. IHC. IF

Specificity

at serine 199

Applications

WB, IHC, IF

Cross-reactivity

Human, Mouse, Rat

Anti-Tau phosphorylated

Western blotting of human control and two Alzheimer brain extracts


Anti-Tau [pS199] Rabbit Polyclonal Antibody - Ref. 4BDX-1502

The Anti-Tau [pS199] antibody (Ref. 4BDX-1502) detects specifically Tau hyperphosphorylation at serine 199 at early steps of neurofibrillary degeneration in human brain tissue or in animal models of tauopathies.


This antibody (Ref. 4BDX-1502) is an early marker of neurofibrillary degeneration as described by Immunohistochemistry in Alzheimer's patients (Maurage et al. 2003).

Interestingly, the neurons of young individuals are also shown to express the serine 199 phosphorylated tau-epitope as published in an article of Maurage et al. 2001

This polyserum is suitable for Western Blot, for Immunohistochemistry and





Immunohistochemistry of neurofibrillary degeneration in Alzheimer patient brain tissue





Anti-APP [pT668] Rabbit Polyclonal Antibody - Ref. 4BDX-1503

Rabbit polyclonal antibody pT668 (Ref. 4BDX-1503) recognizes the phosphorylated threonine 668 of Amyloid Precursor Protein (APP) and is suitable for Western Blot, for Immunohistochemistry and Immunofluorescence. Our polyclonal antibody against APP at phosphorylated Thr-668 is useful tool to detect **phosphorylated APP** in rat, mice or human brain. This antibody (Ref. 4BDX-1503) worked greatly in immunohistochemistry and in immunofluorescence protocols and is a biomarker of neuritic processes surrounding amyloid deposits.










Specificity Anti-APP phosphorylated at threonine 668 Cross-reactivity Human, Mouse, Rat Applications WB, IHC, IF



More informations about SPQI – 4BioDx Company and innovative products

The main goal of SPQI S.A.S is to provide to researchers worldwide innovative high-quality, robust and innovative laboratory reagents tools in neurodegenerative diseases and in male fertility fields. All 4BioDx® reagents are for Research Use Only and are not intended for Diagnostic or Therapeutic Use. Available worldwide thanks to our partners and distributor (complete list upon request). Check out our website (www.4biodx.com) for more details about our innovative products and any release of new products.

All 4BioDx® products are manufactured in France.

Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D and Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curl Alzheimer Res. 9(4):397-405. Sergeant N. Bretteville A. Hamdane M. Caillet-Boudin ML. Grognet P. Bombois S. Blum D. Delacourte A. Pasquier F. Vanmechelen E. Schraen-Maschke S. and Buee L (2008) Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert review of

proteomics 5:207–224.

Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Evrard C, Le Fur N, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Blum D, Hamdane M, Buée L, Melnyk P. New piperazine multi-effect

drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. Neurobiol Dis. 2019 Sep;129:217-233.

Tautou M, Eddarkaoui S, Descamps F, Larchanché PE, El Bakail J, Goveas LM, Dumoulin M, Lamarre C, Blum D, Buée L, Melnyk P, Sergeant N. A B-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration. Front Pharmacol. 2021 Jun 29;12:2679335. Lam S. Petit F. Herard AS. Boluda S. Eddarkaoui S. Guillermier M. The brain bank Neuro-CEB neuropathology network. Buee L. Duyckaerts C. Haik S. Picg JL. Dhenain M. Amyloid and tau pathologies, cognitives impairments and cerebral atrophy after Alzheimer brain

extracts inoculation in a primate. Acta Neuropath. 2021 (in press).





